BioSpace News Archive

Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”) today announced that it will release its fourth quarter and full year 2022 financial results after the market closes on Tuesday, February 28, 2023.

Electromed, Inc., a leader in innovative airway clearance technologies, announced that Kathleen Skarvan will retire as President and Chief Executive Officer with a target effective date on or around July 1, 2023.

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will report fourth quarter and full year 2022 financial results on Monday, February 27, 2023, after the close of the U.S. financial markets.

Vapotherm, Inc. (NYSE: VAPO), (“Vapotherm” or the “Company”) today announced that it closed its previously announced private placement on February 10, 2023, for the issuance and sale of 17,502,244 shares of its common stock and pre-funded warrants to purchase up to 4,402,508 shares of its common stock.

Mirati Therapeutics, Inc. (NASDAQ: MRTX), a targeted oncology company, will announce financial results for the fourth quarter and full year of 2022 along with recent corporate updates on February 28, 2023.

Theratechnologies Inc. (TSX: TH) (NASDAQ: THTX) (“Theratechnologies”), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it will report financial results for its fourth quarter and full year fiscal 2022 ended November 30, on Tuesday, February 28, 2023.

Sio Gene Therapies Inc. (NASDAQ: SIOX) today provided financial results for its fiscal third quarter ended December 31, 2022.

Huntsville, Alabama-based technology company Curiteva announces the first FDA 510(k) cleared 3D-printed PEEK implant, the Inspire Porous PEEK Cervical Interbody System with HAFUSE Technology.

Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and TSX-V: ACST), a late-stage, specialty pharma company advancing three clinical stage drug candidates addressing rare and orphan diseases, today announced financial and operational results for the third quarter ended December 31, 2022

TELA Bio, Inc. announced a three-year dual-source agreement in the biosynthetic category with one of the Nation’s group purchasing organizations.